ICER says Amgen’s tezepelumab ‘likely to be too expensive’Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it Share XICER says Amgen’s tezepelumab ‘likely to be too expensive’https://pharmaphorum.com/news/icer-says-amgens-tezepelumab-likely-to-be-too-expensive/
Amgen builds case for severe asthma drug tezepelumabAmgen and partner AstraZeneca have said their recently filed severe asthma drug tezepelumab has shown impressive results in Share XAmgen builds case for severe asthma drug tezepelumabhttps://pharmaphorum.com/news/amgen-builds-case-for-severe-asthma-drug-tezepelumab/
AZ, Amgen get speedy FDA review for asthma drug tezepelumabThe FDA has started a priority review of AstraZeneca and Amgen’s severe asthma antibody tezepelumab, setting a date Share XAZ, Amgen get speedy FDA review for asthma drug tezepelumabhttps://pharmaphorum.com/news/az-amgen-get-speedy-fda-review-for-severe-asthma-drug-tezepelumab/
AZ trumpets tezepelumab data as filing for severe asthma loomsAstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to Share XAZ trumpets tezepelumab data as filing for severe asthma loomshttps://pharmaphorum.com/news/az-trumpets-tezepelumab-data-as-filing-for-severe-asthma-looms/
AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialAstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a Share XAZ, Amgen’s asthma hope tezepelumab flunks phase 3 trialhttps://pharmaphorum.com/news/az-amgens-asthma-hope-tezepelumab-flunks-phase-3-trial/
Breakthrough designation AstraZeneca’s severe asthma drugThe first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after Share XBreakthrough designation AstraZeneca’s severe asthma drughttps://pharmaphorum.com/news/astrazeneca-asthma-breakthrough/
